Shanghai Haohai Biological Technology , Ltd. Return on Equity

Shanghai Haohai Biological Technology , Ltd. (688366.SS) currently reports a ROE of 2.06%. That is above the Healthcare sector average of -75.84%. Use the charts on this page to explore Shanghai Haohai Biological Technology , Ltd.'s ROE history and peer comparisons.

Shanghai Haohai Biological Technology , Ltd.'s ROE of 2.06% is higher than the Healthcare sector average of -75.84%. That is roughly 102.7% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Shanghai Haohai Biological Technology , Ltd.'s current 2.06% should be judged against Healthcare norms (sector average: -75.84%) and against 688366.SS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 2.06%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.84%. From there, open related valuation or income-statement pages for Shanghai Haohai Biological Technology , Ltd., and consider following 688366.SS for alerts when major investors trade the stock.

Shanghai Haohai Biological Technology , Ltd. is classified in the Healthcare sector. On ROE, it currently shows 2.06% versus a sector average near -75.84%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing 688366.SS with unrelated industries.